Lyka Labs has reported an update on its ongoing Scheme of Amalgamation proceedings at the National Company Law Tribunal (NCLT), Ahmedabad Bench. The NCLT has extended the deadline for the Income Tax Department to submit their reply, granting an additional 15 days beyond the initially allocated 7-day period.

Extension Details

The extension was requested by the lead counsel for the Income Tax Department, citing a recent change in legal representation. The new counsel, who has replaced Ms. Maithili Mehta, required additional time to receive instructions from the department and prepare their response.

Key Dates

Background

This development follows Lyka Labs' earlier intimation dated September 18, 2025, which informed stakeholders that the NCLT had initially directed the Income Tax Department to submit its report within seven days.

Company's Disclosure

Lyka Labs has promptly disclosed this information to the stock exchanges, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also made the NCLT order available on its website ( www.lykalabs.com ) for public access.

Impact and Outlook

While the extension delays the proceedings, it ensures that all parties have adequate time to prepare their submissions. Shareholders and potential investors should note that this is a procedural development in the ongoing amalgamation process, and its full implications will become clearer as the case progresses.

Investors are advised to keep track of further updates from the company regarding the amalgamation proceedings and their potential impact on Lyka Labs' corporate structure and operations.

Lyka Labs Limited has announced a crucial board meeting scheduled for September 29, 2025, to address significant corporate matters. The pharmaceutical company's Board of Directors is set to convene and deliberate on several key issues that could impact its financial structure and corporate governance.

Preference Share Redemption

One of the primary agenda items for the meeting is the consideration of redeeming 1,08,570 unlisted 10% Cumulative Redeemable Preference Shares. These shares, valued at Rs.100 each, represent a total redemption value of approximately Rs.1.09 crore. This move, if approved, could potentially affect the company's capital structure and signal a strategic financial decision.

Appointment of Key Personnel

The board will also discuss the appointment of a Company Secretary and Compliance Officer. This position is crucial for ensuring adherence to regulatory requirements and maintaining effective corporate governance practices. The appointment could strengthen Lyka Labs' compliance framework and investor relations.

Additional Business Matters

While the preference share redemption and key appointment are the highlighted items, the board meeting will also address other business matters. The nature of these additional items has not been specified in the announcement.

Regulatory Compliance

In line with regulatory requirements, Lyka Labs has duly informed both the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange) about the upcoming board meeting and its agenda. This transparency aligns with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Statement

Yogesh Shah, Whole-time Director and CFO of Lyka Labs Limited, signed the official intimation of the board meeting. The company has also made this information available on its website, www.lykalabs.com , ensuring easy access for all stakeholders.

Investors and market watchers will likely keep a close eye on the outcomes of this board meeting, particularly regarding the potential redemption of preference shares and the appointment of key personnel. These decisions could have implications for Lyka Labs' financial strategy and corporate structure going forward.